Myocardial infarction, or heart attack, is the leading cause of mortality globally. Although the treatment of myocardial infarct has improved significantly, scar tissue that persists can often lead to increased stress and adverse remodeling of surrounding tissue, and ultimately to heart failure. Intra‐myocardial injection of biomaterials represents a potential treatment to attenuate remodeling, mitigate degeneration and reverse the disease process in the tissue. In vivo experiments on animal models have shown functional benefits of this therapeutic strategy. However, a poor understanding of the optimal injection pattern, volume and material properties has acted as a barrier to its widespread clinical adoption. In this study, we developed tw...
The intramyocardial injection of biomaterials is an emerging therapy for myocardial infarction. Comp...
Heart failure (HF) post-myocardial infarction (MI) is a leading cause of death in the United States....
Myocardial infarction causes part of the left ventricle muscle to not receive adequate oxygen supply...
Myocardial infarction, or heart attack, is the leading cause of mortality globally. Although the tre...
Myocardial infarction, or heart attack, is the leading cause of mortality globally. Although the tre...
Heart failure is an important medical disease and impacts millions of people throughout the world. I...
International audienceInjection of biomaterials into diseased myocardium has been associated with de...
Includes abstract.Includes bibliographical references.Cardiovascular diseases account for one third ...
Intramyocardial delivery of biomaterials is a promising concept for treating myocardial infarction. ...
Biomaterial injection is a potential new therapy for augmenting ventricular mechanics after myocardi...
Biomaterial injectates are promising as a therapy for myocardial infarction to inhibit the adverse v...
The canonical mechanism of wound healing is disrupted following a myocardial infarction (MI), manife...
Cardiovascular diseases such as myocardial infarction and pulmonary arterial hypertension cause mala...
Heart failure (HF) is one of the leading causes of death and impacts millions of people throughout t...
The intramyocardial injection of biomaterials is an emerging therapy for myocardial infarction. Comp...
Heart failure (HF) post-myocardial infarction (MI) is a leading cause of death in the United States....
Myocardial infarction causes part of the left ventricle muscle to not receive adequate oxygen supply...
Myocardial infarction, or heart attack, is the leading cause of mortality globally. Although the tre...
Myocardial infarction, or heart attack, is the leading cause of mortality globally. Although the tre...
Heart failure is an important medical disease and impacts millions of people throughout the world. I...
International audienceInjection of biomaterials into diseased myocardium has been associated with de...
Includes abstract.Includes bibliographical references.Cardiovascular diseases account for one third ...
Intramyocardial delivery of biomaterials is a promising concept for treating myocardial infarction. ...
Biomaterial injection is a potential new therapy for augmenting ventricular mechanics after myocardi...
Biomaterial injectates are promising as a therapy for myocardial infarction to inhibit the adverse v...
The canonical mechanism of wound healing is disrupted following a myocardial infarction (MI), manife...
Cardiovascular diseases such as myocardial infarction and pulmonary arterial hypertension cause mala...
Heart failure (HF) is one of the leading causes of death and impacts millions of people throughout t...
The intramyocardial injection of biomaterials is an emerging therapy for myocardial infarction. Comp...
Heart failure (HF) post-myocardial infarction (MI) is a leading cause of death in the United States....
Myocardial infarction causes part of the left ventricle muscle to not receive adequate oxygen supply...